HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) with a maintained price target of $36.
May 13, 2024 | 10:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating and a $36 price target on 4D Molecular Therapeutics, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $36 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in the future performance of 4D Molecular Therapeutics. This endorsement is likely to instill confidence in investors and could lead to a positive short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100